1. How I treat cancer-associated venous thromboembolism
by Noémie Kraaijpoel, and Marc Carrier
Blood
Volume 133(4):
January 24, 2019
©2019 by American Society of Hematology

2. Treatment algorithm.
Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested treatment algorithm for catheter-related thrombosis in cancer patients. *In patients with isolated single subsegmental PE without concomitant DVT, consider withholding anticoagulant therapy in patients at high risk of bleeding. **Edoxaban is initiated after a LMWH lead-in of at least 5 days. §Assess drug-drug interactions and bleeding risk during follow-up and consider changing the anticoagulant treatment regimen accordingly. †The decision to continue anticoagulant treatment beyond 6 months should also balance the risk of recurrent VTE and bleeding complications in combination with patients’ preference, life expectancy, and treatment costs. ¥LMWH is currently the preferred treatment option. DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin.
Noémie Kraaijpoel, and Marc Carrier Blood 2019;133:
©2019 by American Society of Hematology